PTC Therapeutics Files 8-K Report
Ticker: PTCT · Form: 8-K · Filed: May 20, 2024 · CIK: 1070081
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
PTC Therapeutics filed an 8-K, mostly procedural stuff. Check full filing for details.
AI Summary
On May 20, 2024, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD Disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates PTC Therapeutics is adhering to regulatory reporting requirements. Investors should review the full document for any material updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, indicating routine regulatory compliance rather than a specific event with immediate high risk.
Key Players & Entities
- PTC THERAPEUTICS, INC. (company) — Filer
- May 20, 2024 (date) — Date of Report
- 500 Warren Corporate Center Drive (address) — Business Address
- Warren, NJ (location) — Business Address City/State
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the company is PTC THERAPEUTICS, INC.
On what date was this 8-K report filed or reported as of?
The report was filed as of May 20, 2024.
Where is PTC Therapeutics, Inc. headquartered?
PTC Therapeutics, Inc. is located at 500 Warren Corporate Center Drive, Warren, NJ.
What is the Commission File Number for PTC Therapeutics, Inc.?
The Commission File Number for PTC Therapeutics, Inc. is 001-35969.
Filing Stats: 584 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-05-20 07:20:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
Filing Documents
- tmb-20240520x8k.htm (8-K) — 44KB
- tmb-20240520xex99.htm (EX-99) — 29KB
- 0001558370-24-008446.txt ( ) — 223KB
- tmb-20240520.xsd (EX-101.SCH) — 4KB
- tmb-20240520_def.xml (EX-101.DEF) — 13KB
- tmb-20240520_lab.xml (EX-101.LAB) — 18KB
- tmb-20240520_pre.xml (EX-101.PRE) — 12KB
- tmb-20240520x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 20, 2024, PTC Therapeutics, Inc. issued a press release announcing that the European Commission has decided not to adopt the negative opinion issued by the Committee for Medicinal Products for Human Use (the "CHMP") of the European Medicines Agency for the renewal of the conditional marketing authorization for Translarna TM (ataluren) and has returned the opinion to the CHMP for re-evaluation . The press release is furnished as Exhibit 99.1 to this Report The information in this Item 7.01 of this Report, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 20, 2024 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: May 20, 2024 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer